| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gudrun M S Nys, Patrick Santens, Guy Vingerhoet. Horizontal and vertical attentional orienting in Parkinson's disease. Brain and cognition. vol 74. issue 3. 2011-02-23. PMID:20801575. |
patients with parkinson's disease (pd) typically suffer from an asymmetric degeneration of dopaminergic cells in the substantia nigra, resulting in right-sided (rpd) or left-sided (lpd) predominance of motor symptomatology. |
2011-02-23 |
2023-08-12 |
Not clear |
| Lakshmi Nayak, Claire Henchcliff. Rasagiline in treatment of Parkinson's disease. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728823. |
rasagiline (n-propargyl-1 (r)-aminoindan) is a novel propargylamine, irreversible, selective monoamine oxidase inhibitor for treatment of parkinson's disease (pd), a progressive condition associated with degeneration of dopaminergic neurons in the substantia nigra. |
2011-02-22 |
2023-08-12 |
Not clear |
| Richard Kone. Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. vol 25. issue 4. 2011-02-17. PMID:20702843. |
pathological hallmarks of parkinson's disease are destruction of dopaminergic neurons in the basal ganglia, especially the substantia nigra, and the presence of lewy bodies within nerve cells. |
2011-02-17 |
2023-08-12 |
Not clear |
| Jacquelyn A Brown, Ryan J Emnett, Crystal R White, Carla M Yuede, Sara B Conyers, Karen L O'Malley, David F Wozniak, David H Gutman. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Human molecular genetics. vol 19. issue 22. 2011-02-17. PMID:20826448. |
the reduction in striatal da levels in nf1 opg mice is associated with reduced striatal expression of tyrosine hydroxylase, the rate-limited enzyme in da synthesis, without any associated dopaminergic cell loss in the substantia nigra. |
2011-02-17 |
2023-08-12 |
mouse |
| Ik Hyun Kwon, Hyun Sook Choi, Kun Seong Shin, Byung Koo Lee, Chong Kil Lee, Bang Yeon Hwang, Sung Cil Lim, Myung Koo Le. Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease. Neuroscience letters. vol 486. issue 1. 2011-02-16. PMID:20851167. |
these results suggested that berberine aggravated 6-ohda-induced cytotoxicity in pc12 cells, and led to the degeneration of dopaminergic neuronal cells in the substantia nigra of 6-ohda-lesioned rats. |
2011-02-16 |
2023-08-12 |
rat |
| Carsten Nicolas Boehler, Nico Bunzeck, Ruth M Krebs, Toemme Noesselt, Mircea A Schoenfeld, Hans-Jochen Heinze, Thomas F Münte, Marty G Woldorff, Jens-Max Hop. Substantia nigra activity level predicts trial-to-trial adjustments in cognitive control. Journal of cognitive neuroscience. vol 23. issue 2. 2011-02-11. PMID:20465358. |
in particular, dopaminergic projections from the midbrain (i.e., from the substantia nigra [sn] and the ventral tegmental area) have been proposed to play a pivotal role in modulating the activity in these areas for cognitive control purposes. |
2011-02-11 |
2023-08-12 |
Not clear |
| Shane Grealish, Bengt Mattsson, Peter Draxler, Anders Björklun. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. The European journal of neuroscience. vol 31. issue 12. 2011-01-25. PMID:20529122. |
the aim of the present study was to characterise the behavioural deficits observed after injection of 6-hydroxydopamine unilaterally into the substantia nigra, and correlate the behavioural impairments with the extent of damage to the mesostriatal dopaminergic pathway. |
2011-01-25 |
2023-08-12 |
mouse |
| Amber Young, Kristin S Assey, Carla D Sturkie, Franklin D West, David W Machacek, Steven L Stic. Glial cell line-derived neurotrophic factor enhances in vitro differentiation of mid-/hindbrain neural progenitor cells to dopaminergic-like neurons. Journal of neuroscience research. vol 88. issue 15. 2011-01-25. PMID:20857516. |
parkinson's disease (pd) affects the motor system through the degeneration of the dopaminergic neurons of the substantia nigra. |
2011-01-25 |
2023-08-12 |
human |
| Jes Paul, M S Nandhu, Korah P Kuruvilla, C S Paulos. Dopamine D₁ and D₂ receptor subtypes functional regulation in corpus striatum of unilateral rotenone lesioned Parkinson's rat model: effect of serotonin, dopamine and norepinephrine. Neurological research. vol 32. issue 9. 2011-01-24. PMID:20887679. |
the hallmark pathology remains in the dopaminergic striatal insufficiency and degeneration of dopaminergic neurons in the substantia nigra. |
2011-01-24 |
2023-08-12 |
rat |
| Ming Gu. What have we learned from Drosophila models of Parkinson's disease? Progress in brain research. vol 184. 2011-01-21. PMID:20887867. |
parkinson's disease (pd) is characterized clinically by motor symptoms such as resting tremor, slowness of movement, rigidity, and postural instability, and pathologically by the degeneration of multiple neuronal types, including, most notably, dopaminergic (da) neurons in the substantia nigra. |
2011-01-21 |
2023-08-12 |
drosophila_melanogaster |
| Christopher J Barnum, Malú G Tanse. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Progress in brain research. vol 184. 2011-01-21. PMID:20887872. |
the molecular mechanisms underlying the pathogenesis of idiopathic parkinson's disease (pd) have not been completely elucidated; however, some progress has been made in identifying factors that compromise survival of the dopaminergic neurons in the substantia nigra (sn) the death of which give rise to the motor symptoms that enable clinicians to diagnose the disease in its mid- to late stages. |
2011-01-21 |
2023-08-12 |
Not clear |
| Joseph K Eibl, Zouleika Abdallah, Gregory M Ros. Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stress. Canadian journal of physiology and pharmacology. vol 88. issue 3. 2011-01-18. PMID:20393595. |
at the cellular level, it is clear that the pathology of pd results from the progressive loss of dopaminergic neurons in the substantia nigra. |
2011-01-18 |
2023-08-12 |
Not clear |
| Carolina A Braga, Cristian Follmer, Fernando L Palhano, Elias Khattar, Mônica S Freitas, Luciana Romão, Saviana Di Giovanni, Hilal A Lashuel, Jerson L Silva, Debora Fogue. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. Journal of molecular biology. vol 405. issue 1. 2011-01-18. PMID:21050861. |
parkinson's disease (pd) is a movement disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of intraneuronal inclusions called lewy bodies, which are composed mainly of α-synuclein (α-syn). |
2011-01-18 |
2023-08-12 |
Not clear |
| Hironori Yokoyama, Ryohei Yano, Hayato Kuroiwa, Tatsuya Tsukada, Hiroto Uchida, Hiroyuki Kato, Jiro Kasahara, Tsutomu Arak. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metabolic brain disease. vol 25. issue 2. 2011-01-13. PMID:20424905. |
our western blot analysis and immunohistochemical study showed that the post-treatment with zonisamide prevented significantly dopaminergic cell damage, the depletion of tyrosine-hydroxylase (th) protein levels and the proliferation of microglia in the striatum and/or substantia nigra 8 days after mptp treatment. |
2011-01-13 |
2023-08-12 |
mouse |
| Almas Siddiqui, Jyothi K Mallajosyula, Anand Rane, Julie K Anderse. Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiology of disease. vol 40. issue 2. 2011-01-12. PMID:20655384. |
these include a specific, selective and progressive loss of dopaminergic neurons of the substantia nigra (sn), selective decreases in mitochondrial complex i (ci) activity and increased oxidative stress. |
2011-01-12 |
2023-08-12 |
mouse |
| Zaineb Henderson, Nazia Matto, Danielle John, Natalia N Nalivaeva, Anthony J Turne. Co-localization of PRiMA with acetylcholinesterase in cholinergic neurons of rat brain: an immunocytochemical study. Brain research. vol 1344. 2011-01-10. PMID:20471375. |
prima label was absent from neighboring gabaergic neurons, and from other neurons of the brain known to express high levels of ache enzymic activity including cranial nerve motor neurons and dopaminergic neurons of the substantia nigra zona compacta. |
2011-01-10 |
2023-08-12 |
rat |
| Michela Deleidi, Penelope J Hallett, James B Koprich, Chee-Yeun Chung, Ole Isacso. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 30. issue 48. 2011-01-06. PMID:21123556. |
in parkinson's disease (pd), loss of striatal dopaminergic (da) terminals and degeneration of da neurons in the substantia nigra (sn) are associated with glial reactions. |
2011-01-06 |
2023-08-12 |
rat |
| Silvia Zucchelli, Marta Codrich, Federica Marcuzzi, Milena Pinto, Sandra Vilotti, Marta Biagioli, Isidro Ferrer, Stefano Gustincic. TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains. Human molecular genetics. vol 19. issue 19. 2011-01-04. PMID:20634198. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and the formation of ubiquitin- and alpha-synuclein (asyn)-positive cytoplasmic inclusions called lewy bodies (lbs). |
2011-01-04 |
2023-08-12 |
human |
| Yoshihisa Kitamur. [Dopaminergic neuroprotection and reconstruction of neural network tiara]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 130. issue 10. 2010-12-30. PMID:20930477. |
parkinson's disease (pd) is an age-related neurodegenerative disorder in whose brain massive loss of dopaminergic neurons and formation of lewy bodies occur in the substantia nigra (sn). |
2010-12-30 |
2023-08-12 |
mouse |
| Bonnie G Garcia, M Diana Neely, Ariel Y Deutc. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cerebral cortex (New York, N.Y. : 1991). vol 20. issue 10. 2010-12-28. PMID:20118184. |
striatal medium spiny neurons (msns) receive glutamatergic afferents from the cerebral cortex and dopaminergic inputs from the substantia nigra (sn). |
2010-12-28 |
2023-08-12 |
Not clear |